AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11730179
Drug: Flunisolide 500
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide 500 and 1,000 microg, twice daily
Trial: 11730179
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 7.5 mg daily
Trial: 9155405
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for diarrhea
Trial: 31857300
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow (NHF) therapy
Trial: 12787319
Drug: Small molecule
RxNorm normalized name: Small molecule melanocortin 4 receptor agonist
DrugBank: LB54640 (DB18331)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule mimetics
Trial: 10918646
Drug: Loop diuretic
RxNorm normalized name: Loop diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loop diuretic therapy
Trial: 10918646
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous beta blockade
Trial: 10918646
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers or magnesium
Trial: 1640282
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three vaccines (PRP‐OMP, PRP‐T, HbOC)
Trial: 6725168
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group ($5.00 for providing a specimen twice weekly)
Trial: 24582119
Drug: fesoterodine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fesoterodine (8 mg)
Trial: 24582119
Drug: tolterodine extended‐release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine extended‐release (4 mg)
Trial: 22086749
Drug: First Generation
RxNorm normalized name: First generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Generation Antipsychotics (FGAs) - Haloperidol or Trifluoperazine
Trial: 8092094
Drug: Moderately protein‐restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately protein‐restricted diet (0.8 g.kg body wt‐1.d‐1)
Trial: 8092094
Drug: Unrestricted protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unrestricted protein diet (> 1.6 g.kg body wt‐1.d‐1)
Trial: 2679238
Drug: Cimetidine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 7.5 mg/kg (group 1)
Trial: 2679238
Drug: Ranitidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 1.5 mg/kg (group 2)
Trial: 2679238
Drug: Ranitidine 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 2.0 mg/kg (group 3)
Trial: 1189983
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vitamin K1 (Konakion) administered intravenously
Trial: 1189983
Drug: Warfarin (Marevan)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (Marevan)
Trial: 1189983
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vitamin K1 (Konakion)
Trial: 25675062
Drug: Lumbar interlaminar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Trial: 25675062
Drug: Lumbar interlaminar
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Trial: 25675062
Drug: Successful group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful group of lumbar interlaminar epidural injections of local anesthetic (lidocaine 0.5%) 6 mL
Trial: 25675062
Drug: Successful group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful group of lumbar interlaminar epidural injections with local anesthetic (lidocaine 0.5%) 5 mL mixed with 1 mL of steroids and 6 mg of betamethasone
Trial: 24056293
Drug: AT substitution
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT substitution in children with AT activity below 0.55 kIU/l (n = 36)
Trial: 24056293
Drug: Prolonged continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged continuous ASP treatment
Trial: 22448235
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/d for 18 months
Trial: 19110158
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein greater than 3.2 mg/dL
Trial: 19110158
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ulcer depth and C-reactive protein
Trial: 19110158
Drug: Ulcer depth
RxNorm normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ulcer depth greater than 3 mm or C-reactive protein greater than 3.2 mg/dL
Trial: 17227995
Drug: Regimen-DI (intensified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-DI (intensified treatment with six 2-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Trial: 17227995
Drug: Regimen-C (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen-C (conventional treatment with six 3-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 mg/m2/day by 4-hour infusion for 3 days])
Trial: 9736420
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) (enoxaparin, 1.5 mg/kg/day) subcutaneously (sc) once daily for 72 hours
Trial: 9736420
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) (initial infusion rate 450 IU/kg/day) continuous intravenous (iv) for 72 hours
Trial: 779390
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg/kg body weight given intramuscularly 1 hour before anaesthesia
Trial: 779390
Drug: Atropine 0.01
RxNorm normalized name: atropine 0.0194 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.01 mg/kg body weight given intravenously 5 minutes prior to induction
Trial: 779390
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intramuscular and intravenous atropine in the above-mentioned doses
Trial: 779390
Drug: Atropine 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.015 mg/kg body weight intravenously 5 minutes prior to induction
Trial: 779390
Drug: Large doses
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large doses of atropine
Trial: 779390
Drug: Preoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative administration of atropine
Trial: 21374929
Drug: 35 microg
RxNorm normalized name: Ethinyl estradiol 35 microgram and norethindrone 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 microg ethinylestradiol (EE) with 2.0 mg cyproterone acetate/day
Trial: 21374929
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg ethinylestradiol (EE) with 2.0 mg dienogest/day
Trial: 21374929
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg ethinylestradiol (EE) with 3.0 mg drospirenone/day
Trial: 18037776
Drug: losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan (50 mg/day)/HCTZ (12.5 mg/day)
Trial: 18037776
Drug: candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan (8 mg/day)/amlodipine (5 mg/day)
Trial: 10471591
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg of levofloxacin once daily for 14 days
Trial: 10471591
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg of levofloxacin three times weekly for 14 days
Trial: 10471591
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 14 days
Trial: 10471591
Drug: Placebo three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times weekly for 14 days
Trial: 2116819
Drug: pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pirenzepine 50 mg bd
Trial: 24187901
Drug: Calcium supplement
RxNorm normalized name: Calcium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplement plus low-dose aspirin (500 mg carbonate calcium plus 80 mg aspirin)
Trial: 19815692
Drug: Cancer treatment
RxNorm normalized name: Retinoids for cancer treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer treatment
Trial: 16326339
Drug: 0.1% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% levobupivacaine infusion
Trial: 12191747
Drug: Lisinopril 5
RxNorm normalized name: lisinopril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5 mg o.d.
Trial: 9790371
Drug: Methylprednisolone, 16
RxNorm normalized name: MethylPREDNISolone, 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone, 16 mg 3 times daily, tapered over 2 weeks
Trial: 9790371
Drug: Promethazine, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promethazine, 25 mg 3 times daily, continued for 2 weeks
Trial: 1978477
Drug: Remoxipride (90-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride (90-600 mg daily)
Trial: 1978477
Drug: Haloperidol (5-45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5-45 mg daily)
Trial: 26658434
Drug: Uphill sprint
RxNorm normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uphill sprint training (UST) - 10 x 10 sec sprints with 60s recovery on a 7% gradient for six weeks, twice weekly
Trial: 19638366
Drug: Aggressive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive blood pressure lowering targeting SBP <130 mmHg using a combination of amlodipine/valsartan and additional antihypertensive medications as needed.
Trial: 19638366
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure lowering targeting SBP <140 mmHg using a combination of amlodipine/valsartan and additional antihypertensive medications as needed.
Trial: 19352059
Drug: 1.5 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/d MK-4 for 4 weeks
Trial: 12469001
Drug: Tetrabenazine (TBZ)
RxNorm normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (TBZ) at a final mean dose of 62.5 ± 37.4 mg/day (range 25‐150)
Trial: 9469353
Drug: Intensified chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified chemotherapy (V-ICE every 3 weeks)
Trial: 9469353
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (V-ICE every 4 weeks)
Trial: 9469353
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 microg/m2/d for 14 days between chemotherapy cycles
Trial: 2229451
Drug: Ciprofloxacin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (750 mg every 12 hours for 5 days before and 24 hours after quinidine administration)
Trial: 2229451
Drug: Quinidine sulfate
RxNorm normalized name: Quinidine Sulfate
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinidine sulfate (400 mg administered alone)
Trial: 361794
Drug: Prednisone 30
RxNorm normalized name: prednisone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 30 mg daily
Trial: 12577250
Drug: Intravenous amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amifostine
Trial: 31819309
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation and fortification of breast milk (FMS-Aptamil-DANON) during NICU hospitalization, with protein added when milk reached 100 cc/kg/day, increased by 20 cc/kg/day until 150-180 cc/kg/day, stopped when weight reached 1500 grams.
Trial: 24691852
Drug: Topical 0.5
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5 % bupivacaine hydrochloride
Trial: 24691852
Drug: Topical 0.9
RxNorm normalized name: iodine topical 0.9% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.9 % NaCl (saline)
Trial: 12383289
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of piroxicam and dexamethasone
Trial: 30701349
Drug: Psychosexual counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosexual counseling (6 weekly sessions, 90 to 120 min each)
Trial: 17320962
Drug: Vitamin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin therapy (antioxidants plus zinc)
Trial: 17320962
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin therapy
Trial: 11179081
Drug: Oral methionine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methionine loading
Trial: 9735650
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment without drainage
Trial: 9735650
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with tube drainage
Trial: 3395914
Drug: Diltiazem 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 2.0 mg given every 6 h
Trial: 23443254
Drug: Anastrozole treatment
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole treatment in compliant patients
Trial: 23443254
Drug: Anastrozole treatment
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole treatment in non-compliant patients
Trial: 19951540
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy (NPWT) with interrupted suction under a pressure of -16.63 kPa for 24 hours or continuous suction under a pressure of -10.64 kPa for 24 hours.
Trial: 19951540
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CT) with petrolatum gauze overlaid with isotonic saline gauze and dry gauze.
Trial: 9109903
Drug: Clozapine (39
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine (39 mg/day)
Trial: 9109903
Drug: Benztropine (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benztropine (3.0 mg/day)
Trial: 3281872
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth (120 mg administered through an intraoesophageal tube four times a day) + Cimetidine (800 mg at night)
Trial: 3281872
Drug: Cimetidine alone
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine alone (800 mg at night)
Trial: 25915944
Drug: PET/CT-guided dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT-guided dose escalation chemoradiotherapy (group C)
Trial: 25915944
Drug: CT-guided dose
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided dose escalation chemoradiotherapy (group B)
Trial: 19785620
Drug: Pharmaceutical company
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical company sponsorship
Trial: 12105323
Drug: Topiramate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (400 mg/d or maximum tolerated dose)
Trial: 16362532
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg methylprednisolone injection
Trial: 16362532
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone injection
Trial: 16362532
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg methylprednisolone injection
Trial: 16362532
Drug: One or
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One or two injections of methylprednisolone
Trial: 16362532
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (20 mg, 40 mg, 60 mg)
Trial: 11914933
Drug: UFT (uracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT (uracil and tegafur) administered at 400 mg/day for 2 years
Trial: 10885606
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m2 every 3 weeks
Trial: 9865705
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2 every 3 weeks
Trial: 6295270
Drug: Ceftizoxime 2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime 2, 3, or 4 g intravenously
Trial: 29595707
Drug: Naloxone (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.15 mg/kg bolus dose, then 0.2 mg/kg per hour infusion)
Trial: 20079168
Drug: CT scanning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT scanning with 16 x 1.25 mm collimation and a 70 ml contrast injection
Trial: 20079168
Drug: CT with
RxNorm normalized name: Impact with Fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT with 64 x 0.625 mm collimation and 20 ml of contrast injection
Trial: 9620514
Drug: Ketamine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 20 mg
Trial: 9620514
Drug: Alfentanil 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 2 mg
Trial: 9620514
Drug: Ketamine 10
RxNorm normalized name: ketamine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 10 mg + Alfentanil 1 mg
Trial: 9620514
Drug: Ketamine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 2.5 mg + Alfentanil 0.25 mg
Trial: 9620514
Drug: Ketamine 5
RxNorm normalized name: ketamine 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 5 mg
Trial: 7695320
Drug: Amikacin once
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin once daily
Trial: 7695320
Drug: Amikacin twice
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin twice daily
Trial: 2785234
Drug: single-dose cardioplegia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose cardioplegia with a cooling jacket
Trial: 562092
Drug: Diphenidol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenidol (40 mg)
Trial: 562092
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 ml of 0.9% saline)
Trial: 26377300
Drug: Ofatumumab maintenance
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab maintenance treatment (300 mg followed by 1000 mg 1 week later and every 8 weeks for up to 2 years)
Trial: 26377300
Drug: Ofatumumab maintenance
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab maintenance treatment
Trial: 21306322
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with intrathecal morphine (SA)
Trial: 19254583
Drug: Rescue steroid
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue steroid group (betamethasone, 2 12‐mg doses 24 hours apart)
Trial: 15046541
Drug: Fluoxetine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (active comparator for duloxetine)